Compare AbbVie Inc (ABBV) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs iShares Gold Trust — how do they compare? AbbVie Inc trades at $247.66 (market cap $441.94B), while iShares Gold Trust trades at $82.79. The key difference: AbbVie Inc pays a 2.77% dividend while iShares Gold Trust pays none, and AbbVie Inc is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| ABBV | IAU | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $263.58 | $101.57 |
52-Week Low | $197.38 | $62.49 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
IAU, the iShares Gold Trust ETF, is trading at $83.305, up 0.96% with a bullish technical signal overall. The ETF benefits from gold's recent momentum as spot gold approaches $4,430/oz amid cooling inflation data and geopolitical tensions. Moving averages show bullish alignment while oscillators indicate some overbought conditions. Recent news highlights gold's safe-haven appeal with institutional buying and positive price forecasts.
The outlook remains positive given gold's role as an inflation hedge and safe-haven asset, supported by central bank demand and favorable CPI data. Risks include potential Fed policy shifts and dollar strength. Conservative investors favor IAU for its low 0.25% expense ratio and lower volatility compared to mining equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
